RxDoctor Payments DataLook up a doctor →

Rolando Toyos, MD

Ophthalmology · Memphis, TNNPI 1962497826

Payments from drug & device makers

$848,949in general payments, 2019–2025

Across 929 payments — averaging $913.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$152K
  • Oyster Point Pharma, Inc.$144K
  • Sun Pharmaceutical Industries Inc.$107K
  • Lumenis BE LTD$103K
  • Oculus, Inc.$97K
  • ANI Pharmaceuticals, Inc.$50K
  • plus $196K from 37 others

What the payments were for

  • Royalty or licence$580%
  • Consulting fees$85,26811%
  • Speaking & faculty fees$634,19078%
  • Travel & lodging$45,7106%
  • Food & beverage$35,7464%
  • Education$4600%
  • Gifts$7,7411%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$848,949 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$144,406
Medicare patients
235
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CequaCyclosporine24$19,637
ProlensaBromfenac Sodium21$7,308
TyrvayaVarenicline Tartrate11$7,189
Prednisolone Acetate38$1,240
MoxifloxacinMoxifloxacin Hcl31$1,062
Latanoprost55$549
Diclofenac Sodium21$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa$106,869$19,63724 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$4,612$7,30821 claims
Oyster Point Pharma, Inc.Tyrvaya$144,414$7,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →